We are live on ! Find out more
ABG

Ally Bridge Group Portfolio holdings

AUM $124M
1-Year Est. Return 249.88%
This Fund
S&P 500
This Quarter Est. Return
+30.61%
1 Year Est. Return
+249.88%
3 Year Est. Return
+942.29%
5 Year Est. Return
+671.08%
10 Year Est. Return
–
AUM
$82.6M
AUM Growth
+$6.27M
Cap. Flow
-$2.82M
Cap. Flow %
-3.41%
Top 10 Hldgs %
82.89%
Holding
26
New
8
Increased
1
Reduced
3
Closed
9

Top Buys

Rank Stock Value
1
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
+$9.99M
2
GERN icon
Geron
GERN
+$6.04M
3
VRDN icon
Viridian Therapeutics
VRDN
+$5.17M
4
MRNS
Marinus Pharmaceuticals, Inc
MRNS
+$3.34M
5
PRAX icon
Praxis Precision Medicines
PRAX
+$3.27M

Top Sells

Rank Stock Value
1
BLU
BELLUS Health Inc.
BLU
+$8.15M
2
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$7.17M
3
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$6.21M
4
MRSN
Mersana Therapeutics
MRSN
+$4.9M
5
SRPT icon
Sarepta Therapeutics
SRPT
+$2.87M

Sector Composition

Rank Sector Weight
1 Healthcare 94.86%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CTIC
26
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
– –
-550,000
Closed -$2.31M
1
2

Similar funds

MP
Marcho Partners London, United Kingdom $124M AUM 15.03% 1-Year Est. Return
EWP
E-Wealth Partners Minnetonka, Minnesota $124M AUM
WFA
WJ Financial Advisors Killingworth, Connecticut $124M AUM
VWM
Vigil Wealth Management Ponte Vedra Beach, Florida $124M AUM
EI
EDMP Inc Lutz, Florida $124M AUM 19.53% 1-Year Est. Return
TC
Town Capital Bel Air, Maryland $124M AUM
IFO
Intrepid Family Office Sarasota, Florida $124M AUM 37.91% 1-Year Est. Return
CRW
Clarity Retirement & Wealth New Bedford, Massachusetts $124M AUM

Ally Bridge Group's Q2 2023 Portfolio in Review

As of Q2 2023, Ally Bridge Group held 26 positions worth $82.6M, up 8.2% from $76.3M the previous quarter. Its ten largest holdings account for 83% of the portfolio.

Ally Bridge Group withdrew a net $2.82M in Q2 2023, closing 9 positions and reducing 3 holdings. Its most notable exit was BELLUS Health Inc., an estimated $8.15M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, down from 100% a quarter earlier.

Against the trend, Ally Bridge Group opened a new position in Reata Pharmaceuticals, Inc. Class A Common Stock worth $10.8M.

  • Ally Bridge Group's largest Q2 2023 buy was Reata Pharmaceuticals, Inc. Class A Common Stock: 105,558 shares worth $10.8M.
  • Ally Bridge Group added most to MoonLake Immunotherapeutics in Q2 2023, an estimated $499K increase.
  • Ally Bridge Group's biggest Q2 2023 reduction was Merus, cutting an estimated $1.68M.
  • Ally Bridge Group fully exited BELLUS Health Inc. in Q2 2023, selling an estimated $8.15M.
  • Ally Bridge Group's ten largest holdings make up 83% of its $82.6M portfolio in Q2 2023.
  • Ally Bridge Group opened 8 new positions and closed 9 in Q2 2023.
  • Ally Bridge Group's portfolio value rose 8.2% quarter-over-quarter to $82.6M.

Based on Ally Bridge Group's 13F filing for Q2 2023, filed 14 Aug 2023.